Replies to post #179001 on Biotech Values

[DewDiligence]

IDIX—As previously posted, I think Klarman did a deep dive into the IP landscape for HCV nukes and concluded that IDIX has a chance to extract some kind of meaningful settlement (or royalty) from GILD. MRK evidently thinks so too.